- Home
- ESTC vs INCY Comparison
ESTC vs INCY Comparison
Compare ESTC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- INCY
- Stock Information
- Founded
- ESTC 2012
- INCY 1991
- Country
- ESTC Netherlands
- INCY United States
- Employees
- ESTC N/A
- INCY N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ESTC Technology
- INCY Health Care
- Exchange
- ESTC Nasdaq
- INCY Nasdaq
- Market Cap
- ESTC 11.7B
- INCY 13.4B
- IPO Year
- ESTC 2018
- INCY 1993
- Fundamental
- Price
- ESTC $97.43
- INCY $67.38
- Analyst Decision
- ESTC Buy
- INCY Buy
- Analyst Count
- ESTC 26
- INCY 19
- Target Price
- ESTC $132.29
- INCY $74.38
- AVG Volume (30 Days)
- ESTC 1.7M
- INCY 1.8M
- Earning Date
- ESTC 02-27-2025
- INCY 04-29-2025
- Dividend Yield
- ESTC N/A
- INCY N/A
- EPS Growth
- ESTC N/A
- INCY N/A
- EPS
- ESTC N/A
- INCY 0.15
- Revenue
- ESTC $1,429,863,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- ESTC $18.60
- INCY $12.23
- Revenue Next Year
- ESTC $14.44
- INCY $8.89
- P/E Ratio
- ESTC N/A
- INCY $454.93
- Revenue Growth
- ESTC 17.95
- INCY 14.76
- 52 Week Low
- ESTC $69.00
- INCY $50.35
- 52 Week High
- ESTC $123.96
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ESTC 41.82
- INCY 38.27
- Support Level
- ESTC $89.15
- INCY $68.17
- Resistance Level
- ESTC $109.92
- INCY $72.81
- Average True Range (ATR)
- ESTC 6.04
- INCY 2.29
- MACD
- ESTC -1.84
- INCY -0.32
- Stochastic Oscillator
- ESTC 28.16
- INCY 8.61
About ESTC Elastic N.V.
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.